Streetbeat News

Regulatory

VANI

Vivani Medical shares are trading higher after the company announced the FDA cleared the Investigational New Drug Application and lifted the clinical hold on NPM-119.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 12:08 pm

TCJH

Top KingWin Ltd (NASDAQ:TCJH) received a notice from Nasdaq on June 7, 2024, indicating non-compliance with the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 12:05 pm

COLL

Collegium Pharmaceutical has announced that the FDA has granted pediatric exclusivity for its Nucynta franchise. This extends U.S. exclusivity for Nucynta to January 2027 and for Nucynta ER to December 2025.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 12:05 pm

TSLA

Tesla Inc. (NASDAQ:TSLA) has announced that it will increase the price of its Model 3 sedan in the European Union starting July 1, 2024, due to new import tariffs on cars made in China. The company is urging customers to take delivery in June to secure the current price.

Portfolio Pulse from Anan Ashraf

June 13, 2024 | 11:46 am

DIA

QQQ

SPY

USO

U.S. stock markets closed mixed with the S&P 500 and Nasdaq hitting record highs due to lower-than-expected inflation data. The Federal Reserve plans only one rate cut this year, contrary to earlier forecasts. Crude oil prices fell due to increased U.S. crude inventories and a reduced oil demand forecast for 2024. European markets dipped due to the Fed's hawkish stance.

Portfolio Pulse from Akanksha Bakshi

June 13, 2024 | 11:17 am

BRTX

BioRestorative Therapies is in advanced discussions to license its ThermoStem platform to a leading regenerative medicine firm. ThermoStem, which uses brown adipose derived stem cells, could offer new treatments for obesity and metabolic disorders. The platform is protected by a comprehensive patent portfolio.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:08 am

KTTA

Pasithea Therapeutics announced that an independent safety review committee has completed a safety review of data from the first dose cohort in the Phase 1 trial of PAS-004.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:07 am

ALDX

Aldeyra Therapeutics has completed enrollment for its Phase 3 trial of Reproxalap, a treatment for dry eye disease. The company expects to release clinical trial results and potentially resubmit a New Drug Application in the second half of 2024.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:04 am

VANI

Vivani Medical, Inc. (NASDAQ:VANI) announced that the FDA has cleared its Investigational New Drug Application for NPM-119, allowing the commencement of the LIBERATE-1 Phase 1 trial. This trial will evaluate the safety, tolerability, and pharmacokinetics of Vivani’s six-month GLP-1 implant for type 2 diabetes. The study is set to start in the second half of the year. Vivani is also developing other drug implants targeting chronic weight management.

Portfolio Pulse from Akanksha Bakshi

June 13, 2024 | 11:01 am

VANI

Vivani Medical announced that the FDA has cleared its Investigational New Drug (IND) application and lifted the clinical hold for NPM-119, a miniature long-term subdermal GLP-1 drug implant.

Portfolio Pulse from Benzinga Newsdesk

June 13, 2024 | 11:00 am